SEC Tracker
Get the app

Lantern Pharma LTRN

Lantern Pharma reports $17.12M net loss

Proxy statement

Form
DEF 14A
Filed
Importance
Routine
  1. Net loss of $17.12 million for the year ended Dec 31, 2025
  2. Annual Meeting to be held on Dec 1, 2026
  3. Proposals include director elections and stock plan amendments

Written from the DEF 14A on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Lantern Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Kezar Life Sciences KZR public float $33M, Jun 30, 2025
  2. Grace Therapeutics GRCE public float $35M, Sep 30, 2025
  3. Insight Molecular Diagnostics IMDX public float $32M, Jun 30, 2025
  4. Rein Therapeutics RNTX public float $32M, Jun 30, 2025
  5. Yarrow Bioscience VYNE public float $32M, Jun 30, 2025